Introduction ERBB2 is overexpressed in 15-25% of upper gastrointestinal adenocarcinomas. We use a stable lentiviral shRNA model to demonstrate that ERBB2 suppression in upper gastrointestinal adenocarcinomas with documented ERBB2 amplification effectively decreases ERBB2 protein levels and decreases cell viability. Further, we evaluate tumor growth of cells treated with the ERBB2 shRNA. Methods Three upper gastrointestinal adenocarcinoma cells lines with varying ERBB2 levels were treated with one of three separate lentiviral green fluorescent protein (GFP)-labeled ERBB2 shRNA vectors or a nonsilencing control shRNA vector for 6 h. Protein levels on day 6 and cell viability was evaluated on days 3-10. A xenograft in vivo experiment was performed using OE19 cells pretransduced with ERBB2 shRNA to evaluate tumor growth. Results ERBB2 protein levels decreased by 80%. ERBB2 knockdown significantly decreased cell viability in cell lines with high ERBB2 levels. In vivo tumor growth was suppressed in ERBB2-shRNA-treated groups. Conclusion ERBB2 suppression based on a stable lentiviral shRNA transfection system effectively decreases cell viability in cell lines with amplification of ERBB2 as compared to cell lines without overexpression. ERBB2 knockdown significantly decreases tumor growth in vivo. ERBB2-directed therapy may be of benefit in the subset of patients with gastrointestinal adenocarcinomas exhibiting overamplification of ERBB2.
Introduction
The incidence of esophageal adenocarcinoma and esophagogastric junction tumors has increased sixfold since 1970. [1] [2] [3] [4] As shown in a Surveillance, Epidemiology, and End Results (SEER) database review by Devesa et al., the annual rate of esophageal adenocarcinoma alone increased by more than 350% from 1974 to 1994. 3 This rate of increase has made esophageal adenocarcinoma the fastest expanding type of cancer in Western countries when compared to all other cancers known to be increasing in incidence (e.g., two-to threefold increase for melanoma and prostate cancer). Unfortunately, the 5-year survival of esophageal adenocarcinoma is dismal even in the subset of patients who undergo appropriate surgical intervention. The mainstay of treatment is surgery if the primary tumor is resectable. Chemotherapy, usually consisting of 5-fluorouracil, cisplatin, and epirubicin, does not change the overall poor prognosis. Improvements in the treatment of unresectable and late-stage disease remain insignificant. Therefore, the development of other treatment strategies is critical.
Several studies have evaluated genes that are commonly deleted or amplified in upper gastrointestinal (GI) adeno-carcinomas. Of all genes evaluated, reported protooncogenes in upper gastrointestinal adenocarcinomas include c-myc, ERBB2, CCNE1,mdm2, GATA-4, Cathepsin B, CMet, epidermal growth factor receptor (EGFR), and Ras. 5, 6 Of these proto-oncogenes, ERBB2 is amplified in a much higher proportion of samples. In the case of esophageal adenocarcinoma, ERBB2 has been shown to be the most commonly amplified proto-oncogene and is overexpressed in approximately15-40% of tumors evaluated. [5] [6] [7] [8] [9] [10] [11] Similar amplification of ERBB2 has also been noted in gastroesophageal junction and gastric cardia adenocarcinomas. 4, 12, 13 As a member of the epidermal growth factor receptor family, ERBB2 (c-erb-B2, HER-2/neu) is a transmembrane tyrosine kinase receptor. Located on chromosome 17q12, the ERBB2 gene plays a key role in growth factor signal transduction and is also involved in the regulation of cell growth, survival, and differentiation. 14, 15 In its normal state, ERBB2 has no known ligand 16 and must pair with other EGFR receptors for activation. As a tyrosine kinase receptor, it is then autophosphorylated and initiates a phosphorylation cascade that results in activation of multiple intracellular pathways, including MAP kinase and phosphoinositol 3 kinase. However, when ERBB2 is overexpressed as the result of a gene amplification event, it is hypothesized that the receptor homodimerizes. In this state, it remains constitutively active and promotes downstream signaling.
To better understand the effect of ERBB2 knockdown in esophageal and gastric adenocarcinomas, we previously used a transient siRNA model to suppress ERBB2 levels in esophageal and gastric adenocarcinoma cell lines with known ERBB2 amplification. Our study reported that ERBB2 inhibition significantly decreases cell viability via an apoptotic pathway. 17 Of note, there were no significant changes in cell cycle seen in our study. However, siRNA is a transient model in which the toxicity of the transfection reagent used as well as the toxicity of the siRNA itself prevents higher transfection efficiencies. Furthermore, siRNA is readily degraded by RNAses. Therefore, in vitro work performed with siRNA technology cannot proceed to an in vivo model; nor can it be translated into the clinical trial setting. Given these inherent limitations of siRNA, we proceeded to evaluate ERBB2 knockdown on upper gastrointestinal adenocarcinomas using a stable transfection model, via lentiviral ERBB2 shRNA vectors. The purpose of this study was to generate a stable transfection model in order to analyze the effect of ERBB2 knockdown on (1) cell viability in upper gastrointestinal adenocarcinoma cell lines with different levels of ERBB2 expression, and (2) tumor growth in an in vivo model.
We believe that in cell lines with ERBB2 amplification there will be a more significant increase in cell death, correlating with our previous siRNA work. Further, we hypothesize that tumor growth of cells treated with the stable ERBB2 shRNA will be significantly inhibited. We show that ERBB2 knockdown via lentiviral shRNA vectors ( Fig. 1 and Table 1 ) in upper gastrointestinal adenocarcinoma cell lines significantly decreases cell viability in the cell lines known to have ERBB2 amplification. Further, tumor growth is inhibited in cell lines treated with shRNA. Our current data correlate with our previous siRNA study and further strengthen the potential benefit of ERBB2-directed therapies in the subset of patient with ERBB2-amplified upper GI adenocarcinoma tumors.
Materials and Methods

Cell Lines
In the present set of experiments, three upper GI adenocarcinoma cell lines were chosen due to their known varying amount of ERBB2 and compared. A gastric adenocarcinoma cell line, MKN45, was obtained from the Japanese Cancer Research Bank. MKN45 has approximately tenfold amplification of ERBB2. 18 An esophageal adenocarcinoma cell line, OE19, was obtained from the European Collection of Cell Cultures. This cell line has 100-fold amplification of ERBB2. 18 Finally, a cell line with a baseline level of ERBB2, Seg-1 (a gift from Dr. David Beer, University of Michigan, Ann Arbor), was used as a control. All cell lines were cultured in Dulbecco's modified essential medium (DMEM), 5% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% amphotericin B. HEK293T cells (ATCC) were used for lentiviral Table 1 . viral tittering and maintenance. This cell line was maintained in DMEM, 5% FBS, and 1% penicillin-streptomycin. All cells were maintained at 37°C in a humidified atmosphere of 5% CO 2 .
Lentiviral shRNA Generation
Three green fluorescent protein (GFP)-labeled ERBB2 shRNA sequences were purchased from OpenBiosytems (Huntsville, AL, USA), as well as a nonsilencing control shRNA sequence (to determine off-target effects). The referenced names as for the ERBB2 shRNA are V2LHS_17669, V2LHS_17671, and V2LHS_17672. Detailed sequence information for each shRNA used is shown in Table 2 . The University of Minnesota RNAi Core Facility (Minneapolis, MN, USA) then produced Pgipz™ lentiviral shRNA vectors according to the manufacturer's instructions (OpenBiosystems, Huntsville, AL, USA). The TransLentiviral™ GIPZ Packaging System is based on lentiviral vectors developed by Kappes and Wu. 19 In order to select out transfected cells, these lentiviral vectors not only include a GFP label, but they also have a puromycin selection marker as shown in Fig. 1 and Table 1 . Treatment with puromycin after transduction eliminates all non-infected cells.
Treatment of Cells with Lentiviral shRNA Vectors
Prior to starting treatments, viral titers of all vectors were routinely found to be 10 6 -10 7 transforming units (TU) per milliliter. Optimization experiments were carried out with varying amounts of lentivirus (1-100 multiplicity of infection, MOI) to determine that the optimal MOI for transduction without toxicity for each lentiviral vector was a MOI of 10. Finally, a puromycin kill curve was performed with each cell line to determine the optimal amount of puromycin needed for selection without toxicity to transduced cells. In all cell lines, the optimal concentration of puromycin was 7.5 μg/mL.
For generation of a stable transduced cell line, cells were plated in a six-well plate at a density of 2×10 5 cells/well and incubated overnight at 37°C and 5% CO 2 . A transduction media was made, consisting of serum-free antibiotic-free DMEM media and 8 μg/mL of Polybrene. Each lentiviral vector was diluted with transduction media to a MOI 10. Cells were washed with phosphate-buffered saline (PBS) and V2LHS_17669  AGCGCAGATGCGGATCCTGAAA  TAGTGAAGCCACAGATGTA  TTTCAGGATCCGCATCTGCGCC  V2LHS_17671  CGCCCTGGCCGTGCTAGACAAT  TAGTGAAGCCACAGATGTA  ATTGTCTAGCACGGCCAGGGCA  V2LHS_17672 CGCTGAACTGGTGTATGCAGAT TAGTGAAGCCACAGATGTA ATCTGCATACACCAGTTCAGCA Each shRNA sequence is preceded and is followed by a 30-mir sequence which increases subsequent Dicer recognition and specificity. The loop sequences for all shRNAs are identical. ERBB2 shRNA sequences vary slightly in the sense and antisense sequences then 1 mL of diluted virus was added. After 6 h, the lentiviral shRNA media was removed and replaced with DMEM containing serum and antibiotic. Cells treated with serum-free media served as the control and are referred to as nontreated cells. On post-transduction day 1, media was removed and replaced with 2 mL of DMEM containing serum, antibiotic, and 7.5 μg/mL puromycin. After 3-5 days, all non-infected cells were killed, and remaining cells had GFP expression, indicating 100% transduction efficiency. Once cells reached 80% confluence, they were then trypsinized with 0.25% trypsin and placed in a 100-mm culture dish for propagation of cell lines. For cell viability assays, 1×10 3 cells per well were seeded in 96-well plates and then incubated overnight at 37°C. Fifty microliters of the appropriate diluted virus at MOI of 10 in transduction media (described above) was then placed on the appropriate wells for 6 h. After 6 h, the viral-containing media was removed and replaced with serum-containing DMEM. Cells treated with serum-free media served as the control and are referred to as nontreated cells. Cells were then incubated for 3-10 days at 37°C and 5% CO 2 until collection for cell viability.
Determination of ERBB2 by Western Blot Analysis
Cells were treated with shRNA lentivirus as described above. Once placed in 100-mm culture plate, cells were grown to 70% confluence and then collected by trypsinization (0.25% trypsin). Cells were washed with PBS thoroughly. Next, cells were lysed with lysis buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), complete Protease Inhibitor (Roche, Indianapolis, IN, USA) for 2 h at 4°C and cleared by centrifugation for 10 min at 10,000×g twice. Supernatants were collected and then stored at −80°C. Total protein concentration was determined using the Bio-Rad DC protein assay (Bio-Rad Hercules, CA, USA). ERBB2 protein expression was analyzed by Western blotting by loading 75-100 μg samples of total protein from the supernatants onto a 10%SDS-polyacrylamide gel electrophoresis gel. The separated proteins were transferred onto polyvinyllidene diflouride membranes. Nonspecific binding to the membranes was blocked by 2-h incubation in a buffer containing Tris-buffered saline Tween-20 (TBS-T; 10 mM Tris-HCl, pH 7.4, 150 NaCl, 0.05% Tween-20) and 5% nonfat dry milk. The ERBB2 protein was subsequently detected by overnight incubation at 4°C with a monoclonal anti-ERBB2 antibody (sc-7301; 1:250 dilution; from Santa Cruz, Santa Cruz, CA, USA) and then 1-h incubation with a peroxidase-conjugated sheep anti-mouse IgG antibody (1:4,000 dilution), both in TBS-T and 5% bovine serum albumin. Bound secondary antibody was visualized by enhanced chemiluminescense (Thermo Fisher Scientific, Rockford, IL, USA) and autoradiography. Actin expression was used as an internal control (1:10,000 dilution).
Determination of Cell Viability
Cell viability was determined using MTS assay (CellTiter 96® AQ ueous Non-Radioactive Cell Proliferation Assay from Promega, Madison, WI, USA). Briefly, cells were seeded into a 96-well plate at a density of 1×103 cells/well and allowed to adhere overnight. After treatment with lentiviral shRNA, cells were incubated for 3-10 days. Next, 20 μL of [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] and phenazine methosulfate (MTS-PMS) solution was added to each well. Plates were incubated at 37°C for 2 h, after which the absorbance at 490 nm was measured.
In Vivo Antitumor Effect in Esophageal Adenocarcinoma Xenograft Model
To study the effect of ERBB2 shRNA on tumor growth of esophageal adenocarcinoma in vivo, the cell line with 100-fold ERBB2 amplification, OE19, was used. OE19 cells were pretransduced with lentiviral shRNA vectors as described above. After puromycin treatment, all remaining cells expressed GFP, indicating 100% transduction efficiency. Once cells were infected with the appropriate lentiviral ERBB2 shRNA vector, cells were maintained and grown as described above.
Female nu/nu nude mice (Frederick Cancer Research, Frederick, MD, USA; 6-8 weeks of age) were used to establish Esophageal Adenocarcinoma xenografts. The mice were randomized into four groups of five mice each prior to inoculation. The pretransduced lentiviral shRNA OE19 cells were harvested, resuspended in cold PBS, and kept on ice until injected. Per injection site, 4×10 6 cells were inoculated into both flanks of each animal. Therefore, each treatment group had a total of ten tumor sites. The condition of the mice was monitored daily, and the tumor diameter was measured twice a week with calipers. The tumor volume was calculated using the formula: tumor volume=(width 2 ×length)/2. In accordance with institutional approved animal experimental protocol, mice were euthanized when tumors ulcerated or at time of overgrowth of the tumors. All of the animals received humane care based on the guidelines set by the American Veterinary Association. All of the experimental protocols involving live animals were reviewed and approved by the Institutional Animal Care and Use Committee of the University of Minnesota.
Subcutaneous tumors rapidly excised at the end of the treatment and evaluation period. Tumors were then snapfrozen with dry ice and stored at −80°C for protein extraction and analysis of ERBB2 by Western blot, as described above.
Statistical Analysis
Statistical analysis of lentiviral shRNA treatment in vitro and in vivo was performed with a two-tailed t test. Data are expressed as a mean ±SD of at least three sets of results. Results were considered statistically significant when P≤0.05.
Results
Transduction efficiency was measured after puromycin selection by the amount of GFP expression and was consistently 100% for each cell line.
ERBB2 shRNA Treatment of Gastrointestinal Adenocarcinoma Decreases Protein Expression
Transduction with lentiviral ERBB2 shRNA decreased protein levels significantly at 72 h. ERBB2 protein levels decreased by 80% with siRNA treatment in OE19, with similar results seen in both MKN4 and Seg-1 (Fig. 2) . Results were reproduced with all three ERBB2 shRNA.
ERBB2 shRNA Treatment of Gastrointestinal Adenocarcinoma Decreases Cell Viability
The effect of ERBB2 shRNA on the viability of the upper GI adenocarcinoma cancer cells was examined after 6 h incubation with shRNA and incubation with serum containing media for 3-10 days post-infection. The treatment with ERBB2 shRNA significantly reduced cell viability of the two cell lines with known ERBB2 amplification as shown by cell death of 55% by day 7 in MKN45 cells and up to 80% in OE19 cells on day 7 (Table 3 ; Fig. 3 ). The cell line with a normal ERBB2 levels, Seg-1, exhibited no significant reduction in cell viability when compared to nontreated cells and to cells treated with control siRNA (Table 3; Fig. 3 ).
ERBB2 shRNA Treatment of Gastrointestinal Adenocarcinoma In Vitro Decreases Tumor Growth In Vivo
The cell line with the highest amount of ERBB2 amplification, OE19, was chosen for the in vivo model. Tumors were palpable in the control group (mice injected with nonsilencing control shRNA) by day 4. All mice developed tumors. However, given that one animal in the control group developed tumor only in one injection site, the total number of tumors evaluated in the control group was nine. On day 14 after injection, the nonsilencing control shRNA group (relative tumor volume 33.85±14.26; n=9) had significantly larger tumors in comparison to the ERBB2-shRNA-treated groups (Table 4 ; Fig. 4 ). All ERBB2 shRNA tumors had a significantly slower rate of tumor growth as compared to the control group. By day 25, tumors in the control (nonsilencing shRNA) group were 2.5 times larger than all ERBB2-shRNAtreated tumors. Of the tumors evaluated, ERBB2 protein levels were suppressed in five of the six ERBB2 shRNA tumors as compared to the nonsilencing control shRNA tumors (Fig. 4) . This indicates that ERBB2 protein continued to be suppressed in the majority of ERBB2 shRNA tumors. Thus, the in vivo data indicate that ERBB2 suppression does inhibit tumor growth of upper GI adenocarcinomas.
Discussion
In the present study, ERBB2 shRNA treatment significantly decreased protein levels of ERBB2 in all cell lines, indicating that the lentiviral shRNA model is an effective tool to evaluate ERBB2 suppression. Further, ERBB2 shRNA treatment significantly decreased cell viability in our two upper GI adenocarcinoma cell lines with known ERBB2 overexpression (OE19 and MKN45), though it did not affect that of a cell line with a normal level of ERBB2 (Seg-1). These results correlate with results in our earlier work with ERBB2 siRNA in which we found that ERBB2 siRNA significantly decreases cell viability by up to 60% in 3 days. 17 Given that a decrease in cell viability can be the result of an increase in apoptosis, an increase in cell cycle arrest, or a combination of both mechanisms, we also reported that decreased cell viability in this model occurred via an apoptotic pathway. Of note, cell cycle did not significantly change in cell lines treated with ERBB2 siRNA. 17 When evaluated in vivo, we find that treating the cell line with the highest level of ERBB2 amplification with shRNA, tumor growth is significantly slower and less than in tumors of cells treated with a nonsilencing control shRNA. These results also correlate with a similar model by Yang et al. in which breast cancer cells were treated with ERBB2 siRNA and found to have decreased cell viability, increased apoptosis, and decreased tumor growth. 20 Advanced upper gastrointestinal adenocarcinomas are highly aggressive cancers that portray poor long-term prognoses. 3, 21, 22 Curative treatment consists of surgical resection for early-stage disease. Unfortunately, only 20-30% of patients are eligible for surgery secondary to metastases at time of diagnosis, invasion of surrounding structures, or due to multiple comorbidities of the patients. 23, 24 Under current standards of clinical care, there are few treatment options for the majority of patients who cannot undergo surgical resection of their tumors. Neoadjuvant and adjuvant chemotherapy provides patients with little improvement in overall survival rates. Therefore, new therapeutic approaches must be investigated to offer a more effective treatment for unresectable disease. Given that upper gastrointestinal adenocarcinoma is easily accessible via endoscopy, direct injection of ERBB2-directed therapies could provide a beneficial treatment strategy without the systemic toxicities.
The best documented studies involving ERBB2-directed therapy are using the breast cancer model. 25, 26 As seen in these breast cancer models, ERBB2 amplification is ) and MKN45 (C.). In comparison, there were no significant changes in treatment groups in the cell line with a baseline ERBB2, Seg-1 (A.). n=4 *p<0.001 when compared to nonsilencing control shRNA Figure 3 Cell viability assay of upper GI adenocarcinoma after ERBB2 shRNA. Effect of ERBB2 shRNA treatment on upper GI adenocarcinoma cell viability. After 6 h transduction with ERBB2
shRNA, cell viability was significantly reduced in OE19 and MKN45, with no significant change in Seg-1. n=4. **p<0.001 when compared to nonsilencing control shRNA.
documented in 25-40% of tumors evaluated. 25, 26 ERBB2 overepression in breast cancer tumors has been found to be an independent prognostic predictor of overall survival and time to relapse, perhaps due to the increased association with estrogen receptor negativity and early metastasis of these tumors. In this subset of patients, ERBB2-targeted therapies have significantly improved overall survival and disease-free rates of survival. 25, 26 The ERBB2 gene is amplified in several cancers other than breast and upper GI adenocarcinomas, including cancers of the prostate, 27 pancreas, 28 lung, 29, 30 and ovary.
14 Trastuzumab (Herceptin), a humanized monoclonal antibody which binds to the extracellular domain of the HER2 protein, has been used clinically to treat patients with ERBB2-amplified metastatic breast cancers. 26, 31 In previous studies by our lab, this drug also inhibited growth of OE19, an esophageal adenocarcinoma with 100-fold amplification of ERBB2. However, in cell lines with normal ERBB2 levels, cell growth was not inhibited. 5 No clinical trials have yet tested trastuzumab in the subset of patients with known ERBB2-amplified upper GI adenocarcinomas. Unfortunately, there are many obstacles to overcome with the use of herceptin, including the significant side effects (in particular, cardiotoxicity) secondary to systemic administration as well as the cost of treatment (ranging from $20,000 to $80,000/year). Although herceptin therapy may be an effective strategy in a high-risk population, development of treatment with local administration could potentially bypass these obstacles. Therefore, the future direction of our lab is to generate a cost-effective stable transfection model with the potential of local administration.
Lentiviral shRNA vectors provides several advantages over siRNAs. Unlike siRNA, lentiviral vectors are more stable and are not degraded by RNAses. Unlike siRNAs in which expression of suppression is transient, lentiviruses integrate into the host genome as part of their life cycle, and thus their genomic backbone provides a means for life-long expression of ERBB2 shRNA. Further, lentiviruses infect all cells, including actively dividing cells as well as resting and differentiated cells. Given that the lentivirus used is nonreplicative, ERBB2 shRNA is continually expressed, but infectious virus is not generated. However, there are limitations to this model. For example, endogenous expression of shRNA can cause side effects such as the activation of innate immunity via induction of an interferon response. 32 As with siRNA, lentiviral shRNA vectors also have the potential of offtarget gene silencing. However, by evaluating several ERBB2 shRNA in comparison to a nonsilencing control shRNA, the potential of off-target effects is essentially eliminated in this study. Finally, shRNAs have the risk of competition with cellular miRNAs given that they use come of the miRNA machinery for their generation and export.
A stable cost-effective transfection model for ERBB2 suppression of upper GI adenocarcinomas could be an optimal treatment adjunct. Our lab is currently generating replication-incompetent adenoviral ERBB2 shRNA vectors to repeat all experiments. There are several benefits in an adenoviral system, including providing us with a much higher level of initial transient expression. Further, as with the lentiviral model, replication-incompetent adenoviruses are limited in their ability to spread beyond the local injection site, thus generating little systemic effects.
In summary, we have shown that ERBB2 suppression significantly decreases cell viability via an apoptotic pathway 17 and inhibits tumor growth in upper gastrointestinal adenocarcinomas. ERBB2-directed therapy may be of benefit in the subset of patients with gastrointestinal adenocarcinomas exhibiting overamplification of ERBB2. Further studies are clearly warranted to generate improved treatment strategies for patients with unresectable disease.
